Immuno-Oncology

Future Research Efforts for ALK-Driven Lung Cancer

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.

Next Generation ALK Inhibitors for NSCLC

Treatment of ALK-Driven Refractory NSCLC

$Treatment of ALK-Driven Refractory NSCLC$

Sequencing Therapies in ALK+ NSCLC

Upfront Use of Second-Line Agents in ALK+ NSCLC

Treatment of Relapsed/Refractory ALK+ NSCLC

$Treatment of Relapsed/Refractory ALK+ NSCLC$

Repeat Mutation Testing at ALK-Rearranged NSCLC Progression

ALTA II Trial of Brigatinib in ALK-Rearranged NSCLC

FDA Approval of Brigatinib for ALK+ NSCLC

Patterns of Progression on Crizotinib for ALK+ NSCLC

The Evolution of ALK/ROS1-Targeted Therapy in NSCLC

Biomarker Testing in NSCLC to Expand in Near Future

Dr. Zelenetz on Nivolumab Plus Ibrutinib in Patients With CLL

April 26th 2017

Matthew Gubens, MD, discusses how far the field of NSCLC has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

By Andrew D. Zelenetz, MD, PhD

April 26th 2017

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

By Mark A. Socinski, MD

April 26th 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

Expert Stresses Early Detection, Multidisciplinary Care for HCC

By Angelica Welch

Expert Discusses Immunotherapy Advances in Head and Neck Cancer

Amit Singal, MD, discusses the recent successes in the hepatocellular carcinoma treatment landscape and the challenges that still remain.

By Danielle Bucco

Expert Highlights Novel Combos, Potential of Immunotherapy in MCL

Barbara Burtness, MD, discusses her presentation on the current and emerging role of immunotherapy for patients with head and neck cancer.

Dr. Sangro Discusses Safety Profile of Nivolumab in HCC

Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.

By Bruno Sangro, MD, PhD

Dr. Seiwert on Managing Side Effects for Head and Neck Cancer Treatment

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

By Tanguy I. Seiwert, MD

Immunotherapy Revolutionizes NSCLC, But Unanswered Questions Remain

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.